Loading clinical trials...
Loading clinical trials...
This is a Phase 2a efficacy and safety study of EVO301 for the treatment of adults with atopic dermatitis.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Evommune, Inc.
NCT07298395 · Atopic Dermatitis (AD)
NCT06928246 · Atopic Dermatitis (AD)
NCT06096857 · Atopic Dermatitis, Eczema
NCT07316465 · Atopic Dermatitis (AD), Autoantibody, and more
NCT07235384 · Atopic Dermatitis (AD)
Cornerstone Dermatology
Coorparoo
Momentum Clinical Research Darlinghurst
Darlinghurst
Pacific Clinical Research Network (PCRN) Auckland
Auckland
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions